Oligodeoxynucleotides containing CpG motifs (CpG-ODN) are potent in vitro B-cell activators and they have been successfully used to increase in vivo antibody responses to T-dependent peptide and protein antigens. In contrast, the use of CpG-ODN to enhance in vivo antibody responses to various T-independent type 2 (TI-2) antigens has recently generated contradictory results. In this study, we compared the CpG-ODN stimulatory effect on antibody responses of adult and young BALB/c mice to trinitrophenylaminoethyl-carboxymethyl (TNP) -Ficoll and to polysaccharides (PS) from several distinct serotypes of Streptococcus pneumoniae (SPn). CpG-ODN co-administration signi®cantly enhanced antigen-speci®c immunoglobulin M (IgM), IgG, IgG1 and IgG2a titres to TNP-Ficoll. The depletion of CD4 + cells by monclonal antibodies (GK1.5) identi®ed their essential role in CpG-ODN-mediated enhancement of antibody responses. In contrast to TNPFicoll, CpG-ODN failed to enhance IgM and IgG responses to any of the 18 SPnPS serotypes tested. Providing T-cell epitopes by the conjugation of SPnPS to the carrier protein tetanus toxoid again allowed CpG-ODN to mediate enhancement of IgG, IgG2a and IgG3 responses to most SPnPS serotypes. Thus, antigen-presenting cell/T-cell interaction appears to largely mediate the in vivo in¯uence of CpG-ODN on antibody responses to TI-2 antigens. In early life, additional factors limit CpG-ODN modulation of antibody responses to TI-2 antigens.
INTRODUCTION
Thymus-independent type-2 (TI-2) antigens were originally described as evoking primarily immunoglobulin M (IgM) responses, with little or no IgG antibody formation, and were further de®ned as capable of inducing antibody responses in T-cell-de®cient (nu/nu) mice, but not in mice bearing the xid mutation or in young mice.
1,2 Among these TI-2 antigens, distinct polysaccharides (PS) constituting the cell wall of encapsulated bacteria, dextran, or synthetic PS, such as Ficoll, share common features such as large molecular weight, ordered display of multiple identical epitopes and poor biodegradability. 3 Although T cells are not directly primed by TI-2 antigens, a certain regulatory role of T cells and T-cell-or macrophage-derived factors on B-cell responses has been described for most TI-2 antigens, including pneumococcal PS and trinitrophenylaminoethyl-carboxymethyl (TNP) -Ficoll. 3 Recently, mimicking antigen-presenting cell (APC) and T-cell help by co-administration of recombinant interleukin-12 (IL-12) and anti-CD40 monoclonal antibodies (mAb) resulted in a signi®cant increase in antibody titres to pneumococcal PS. 4, 5 Furthermore, although Ficoll was initially considered as a model TI-2 antigen, APC and T cells were later shown to control antibody responses to Ficoll. 6, 7 Thus, TI-2 antigens represent a rather heterogeneous group of different molecules where the nature of the B-cell activation signal(s) is extremely critical for the determination of both the qualitative and quantitative pro®les of immunoglobulin isotype production, probably in response to various cytokines. 3 Although the exact mechanisms responsible for this B-cellstimulatory effect are not yet known, they are likely to involve the induction of immediate early genes such as erg-1, c-fos and c-myc. 9 CpG-ODN sequences have also been demonstrated to strongly activate APC and natural killer (NK) cells, to promote the secretion of cytokines such as IL-6, IL-10, IL-12, IL-18, tumour necrosis factor-a, type I interferons, and interferon-c and to induce the expression of major histocompatibility complex and various co-stimulatory molecules. 10 This activation has been shown to result in a strong increase of antibody and T-cell responses to a variety of protein antigens, as reviewed by Wagner. 10 In contrast, controversial results were recently reported from experiments using CpG-ODN to increase antibody responses to TI-2 antigens. In one study CpG-ODN failed to enhance or even suppressed Pseudomonas aeruginosa-PS-speci®c antibody responses, 11 whereas another study reported that CpG-ODN increases TNP-Ficoll speci®c IgG but not IgM responses. 12 Most recently, CpG-ODN were reported to enhance Hemophilus in¯uenzae b (HIB) vaccine responses, but only when HIB-PS were conjugated to a carrier protein. 13 CpG-ODN administration was also shown to enhance antibody responses against two pneumococcal PS conjugated to a diphtheria toxin protein carrier, 14 but responses to plain, unconjugated pneumococcal PS were not evaluated. To understand better the features of CpG-ODN modulation of antibody responses to TI-2 antigens, we assessed the capacity of CpG-ODN to enhance in vivo antibody responses to TNP-Ficoll and to a panel of distinct Streptococcus pneumoniae (Spn) PS serotypes, which were either administered as plain PS or as protein-conjugated vaccines. Given the potential importance of an enhancement of early-life antibody responses to bacterial PS, and the capacity of CpG-ODN to enhance early-life murine antibody responses to peptide and protein vaccines, 15, 16 we also assessed the in¯uence of CpG-ODN on antibody responses elicited by PS immunization in early life.
MATERIALS AND METHODS

Mice
Speci®c pathogen-free adult BALB/c inbred mice were purchased from BRL (Fu È llinsdorf, Switzerland) and kept under speci®c pathogen-free conditions. Breeding cages were checked daily for new births. Pups were kept with mothers until weaning at the age of 4 weeks. The evaluation of early-life responses was performed in 2-week-old mice, the earliest age allowing preimmunization bleeding. Mice were bled before and at several time-points after immunization at the tail vein except for mice at 2 weeks of age, which were bled retro-orbitally. Antigen formulations were injected subcutaneously (s.c.) in groups of four to eight mice, unless otherwise indicated in the ®gure legends. Aliquots of serum from individual mice were assessed either individually or pooled (by group and timepoint) for the presence of antigen-speci®c antibodies.
Antigens, adjuvants and immunization procedures Pneumovax-23 [Merck, Sharp and Dohuse (MSD), West Point, PA] is a polyvalent pneumococcal vaccine containing 23 different puri®ed cell wall PS from SPn. In our experiments, it was used at a dose of 25 mg (20 ml) of SPnPS per mouse.
5 Pn11-TT, a polyvalent SPn glycoconjugate vaccine containing 11 different puri®ed cell wall PS from SPn individually conjugated to tetanus toxoid (TT), was kindly provided by Pasteur Me Ârieux Connaught (Marcy l'E Â toile, France). It was used at one-®fth of the human dose (0 . 1 mg to 0 . + cells were depleted in mice by weekly intraperitoneal (i.p.) injections of 0 . 3 mg anti-CD4 mAb (GK1.5), starting 1 week before immunization with antigen. The extent of CD4
+ cell depletion was monitored on peripheral blood samples by¯ow cytometry and was generally >95%.
Quanti®cation of antigen-speci®c antibodies
Sera from mice immunized with pneumococcal vaccines, either individual or pooled by experimental groups and time-points, were preadsorbed with Pneumococcal C-polysaccharide (CPS) (Serum Institute Kopenhagen, Denmark, 2 mg/ml), for 1 hr at room temperature. Sera were then tested by enzyme-linked immunosorbent assay (ELISA) on Nunc Maxisorb plates coated with one of several different pneumococcal serotypes (American Type Culture Collection, Manassas, VA), according to the World Health Organisation Consensus Protocol for determination of speci®c pneumococcal antibodies, modi®ed for detection of mouse-speci®c immunoglobulin by use of the relevant isotype-speci®c (IgM, IgG, IgG1, or IgG2a) peroxidase-conjugated goat or rabbit anti-mouse antibodies (Zymed, San Francisco, CA). 17 For the detection of TNP-speci®c antibodies, Nunc Maxisorb plates were coated overnight at 4u with TNP-bovine serum albumin (BSA; Biosearch Technologies, Novato, CA) before saturation with 1% BSA (Sigma, St Louis, MI) in PBS-0 . 05% Tween-20, for 1 hr at room temperature. Sera were diluted in saturation buffer and serial twofold dilutions (starting at 1/100) were incubated for 2 hr at room temperature. After washing, the relevant isotype-speci®c peroxidaseconjugated goat or rabbit anti-mouse antibody (Zymed) was added for 2 hr at 37u prior to washing, incubation with substrate and reading. For both tests antibody levels were expressed as ELISA titres by reference to serial dilution of a previously out-titrated serum pool from immunized adult mice. Antibody titres below the cut-off of the assay were given an arbitrary titre of one-half of the cut-off value in order to allow calculation of geometric mean antibody titres.
Determination of in vitro proliferative responses
Single spleen cell suspensions were prepared from spleens and cultured at 37u in a 5% CO 2 humidi®ed incubator, in RPMI-1640 supplemented with 10% (v/v) heat inactivated fetal calf serum (FCS), 1 . 5 mM L-glutamine, 50 mM 2-mercaptoethanol, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were seeded on to 96-well plates and treated with media or ODN (at the indicated concentrations) at a density of 10 5 cells/200 ml/well. This procedure was previously shown to induce proliferation of only B cells. 8 At the end of the incubation period, cells were pulsed with 1 mCi of [ 3 H]thymidine before harvesting and scintillation counting, as described previously. 8, 17 Standard deviations of the triplicate wells were <5%.
Determination of IgG/IgM titres after in vitro proliferative responses For the detection of IgM and IgG in culture supernatants, spleen cells were seeded into 96-well plates and treated with media or ODN (at the indicated concentrations) at a density of 10 6 cells/200 ml/well. After incubation for 48 hr cell supernatants were harvested and immunoglobulin titres determined by ELISA. Nunc Maxisorb plates were coated overnight at 4u with goat anti-mouse IgG Fc (5 mg/ml) or goat anti-mouse IgM (2 mg/ml) in PBS (Cappel/ICN, Costa Mesa, CA), before saturation with 1% BSA (Sigma) in PBS-0 . 05% Tween-20, for 1 hr at room temperature. Sera were diluted in saturation buffer and twofold serial dilutions of supernatant (starting at 1/2) were incubated overnight at 4u. After washing, peroxidaseconjugated goat anti-mouse IgG or goat anti-mouse IgM (Zymed) were added for 2 hr at 37u prior to washing, followed by incubation with substrate and measurement of optical density (OD). Results of the assays were expressed as ELISA titres by reference to serial dilution of a previously out-titrated serum pool from naõ Ève mice.
Statistical analysis
Signi®cance analysis between results obtained from various groups of mice was performed by using the Mann±Whitney U-test. Differences with probability values >0 . 05 were considered insigni®cant.
RESULTS
CpG-ODN enhance in vivo antibody responses to TNP-Ficoll
Adult BALB/c mice (>8-week-old) were ®rst immunized with 50 mg of AlOH-adjuvanted TNP-Ficoll together with either CpG-or ctr-ODN. CpG-ODN administration signi®cantly enhanced peak TNP-speci®c IgM titres (measured 10 days post-immunization) compared to ctr-ODN (Table 1) . CpG-ODN only slightly enhanced total IgG (not shown) and IgG1 titres, but they markedly increased IgG2a antibodies (Table 1) . When immunization was performed in 2-week-old mice, CpG-ODN administration signi®cantly enhanced IgG1 but not IgG2a responses to TNP-Ficoll (Table 1) . In contrast, when TNP was conjugated to the ovalbumin protein carrier (TNP-OVA), a strong CpG-mediated enhancement of both IgG1 and IgG2a titres was observed regardless of age at immunization (Table 1) . (Fig. 1a±d) and against most other serotypes contained in the vaccine (data not shown). As expected, IgM responses peaked 10 days after priming, with no further increase after booster immunization. In contrast to responses to TNP-Ficoll, CpG-ODN had no signi®cant in¯uence on the magnitude or the kinetics of IgM responses against any of 18/23 tested SPnPS (Fig. 1a±d and data not shown) . CpG-ODN also failed to enhance IgG, IgG2a and IgG3 responses to plain SPnPS. IgG to all tested serotypes remained at very low titres (<1000 ELISA units), regardless of the administration of CpG-or ctr-ODN (data not shown). Modi®cation of the experimental conditions, including the change of the immunization route (i.p. versus s.c.) or addition of AlOH, failed to result in a CpG-ODN-mediated enhancement of IgM/IgG responses to SPnPS. CpG-ODN also failed to enhance IgM (Fig. 1a±d) or IgG (not shown) responses when immunization was performed at 2 weeks of age.
Pneumococcal PS do not interfere with CpG-ODN B-cell activation in vitro
In view of the lack of enhancement of IgM/IgG responses to SPnPS, we asked whether SPnPS could interfere with B-cell activation. Indeed, complex PS taken up by APC are known to be retained for extended periods in the endosomal compartment 18, 19 in which CpG-ODN must undergo acidi®cation or other processing steps in order to be able to bind to cytoplasmic CpG-binding proteins and hence deliver their activation signals to the cell nucleus. 10, 20 Splenocytes from naõ Ève mice were thus incubated in vitro with a mixture of SPnPS and increasing concentrations of CpG-or ctr-ODN, under conditions previously described as leading to B-cell proliferation and polyclonal IgM secretion. 8, 21 As previously observed, 16 B-cell proliferative responses to CpG-ODN stimulation were dose-and age-dependent (Table 2 ). In spite of lower proliferative responses of cells from 1-week-old mice compared to adult mice, CpG-ODN signi®cantly increased polyclonal IgM production from cells of all age groups (Table 2 ). Increasing concentrations of SPnPS (0 . 1±10 mg/ml) remained without inhibitory in¯uence on CpG-ODN mediated B-cell proliferation and IgM production (Table 2) . Thus, the B-cell stimulatory activity mediated by CpG-ODN was not inhibited, at least not in vitro, by the presence of high concentrations of SPnPS. 11 distinct SPnPS individually conjugated to the TT carrier protein (Pn11-TT). As expected, CpG-ODN strongly enhanced total IgG, IgG1 and IgG2a responses to TT, the protein moiety of the vaccine (Table 3) . In contrast, CpG-ODN remained without any in¯uence on SPnPS-speci®c IgM responses induced by Pn11-TT (data not shown). CpG-ODN co-administration signi®cantly enhanced IgG responses for four major serotypes (Fig. 2a±d) , however, the magnitude of this CpG-ODN-mediated enhancement was modest and serotype-dependent. A signi®cant enhancement of both primary and secondary IgG responses in adult mice was observed for serotypes 14, 19/19F, 23/23F and 56/18C (similar to 23/23F, results not shown), whereas responses to serotype 26/6B were not increased (Fig. 2d) . The in¯uence of CpG-ODN on total IgG responses was con®rmed by antibody subclass determination, showing an increase of IgG2a (Fig. 3a±d) and of IgG3 antibody responses, which mirrored the IgG2a responses (data not shown). When Pn11-TT immunization was performed in 2-week-old mice, co-administration of CpG-ODN failed to signi®cantly enhance IgG responses to any serotype of SPnPS (Figs 2 and 3) , in spite of their enhancement of TT-speci®c antibodies (Table 3) . Thus, addition of CD4 T-cell epitopes to SPnPS allowed CpG-ODN to mediate an enhancement of IgG and IgG2a antibody responses, although only to a modest degree and in a serotype-and age-dependent manner.
Role for CD4
+ cells in CpG modulation of antibody responses to TI-2 antigens
The observation of a CpG modulation of antibody responses to TNP-Ficoll and to TT-conjugated SPn but not to unconjugated PS suggested an essential participation for APC/T-cell interaction in the CpG modulation of antibody responses to TI-2 antigens. This was directly assessed in adult mice depleted of CD4
+ cells prior to TNP-Ficoll and CpG-ODN administration. CD4-depletion reduced anti-TNP total IgG measured 3 weeks after immunization in CpG-ODN adjuvanted mice compared to non-depleted mice, such that antibody titres were now similar to those of non-depleted mice immunized with ctr-ODN formulations (Fig. 4) . Similar results were obtained for IgG1 titres (Fig. 4) . CD4 depletion also reduced IgG2a titres following TNP-Ficoll immunization with CpG-ODN, although IgG2a antibodies remained slightly higher than in mice injected with antigen and ctr-ODN (Fig. 4) . Thus, although the depletion of CD4 + cells did not abrogate IgG, IgG1 and IgG2a responses to alum-adsorbed TNP-Ficoll, the CpG-ODN-mediated enhancement of antibody responses was completely (IgG and IgG1) or largely (83%, IgG2a) dependent on CD4 + cells.
DISCUSSION
Our observations indicate that the in vivo enhancement of antibody responses to TI-2 antigens by CpG-ODN is dependent on the nature of the PS antigen. B-cell responses to TNP-Ficoll were enhanced by CpG-ODN-mediated immunostimulatory signals, whereas responses to plain SPnPS were not. Our results suggest that these differences might re¯ect the degree of the participation of other immune cells likely to be modulated by CpG-ODN, such as APC and T cells. Our observation that CpG-ODN enhance both adult and early-life in vivo antibody responses to TNP-Ficoll is in accordance with the recent description of their capacity to enhance the in vitro generation of TNP-Ficoll-speci®c *Mean SI from three experiments (adults) to ®ve experiments (1-week-and 4-week-old mice) and the range (in brackets); {Production of non-speci®c IgM by splenocytes in vitro. Results of a representative experiment; {Pn-23 was added to in vitro cultures in concentrations of 0 . 1 mg/ml to 10 mg/ml (indicated is 10 mg/ml); different experiment to {; ND, not done.
antibody-forming cells by adult and neonatal splenocytes. 21 In vivo, CpG-ODN are shown here to essentially enhance adult IgG2a responses to TNP-Ficoll, similar to their in¯uence on IgG2a responses to protein vaccines 22, 23 and model protein antigens.
24±27 This`T helper type 1 driving' immunomodulatory property of CpG-ODN has been largely associated with their capacity to enhance IL-12 production by APC, 28 which suggests that TNP-Ficoll responses may be in¯uenced by APC activation. In contrast, CpG-ODN failed to increase IgG2a responses in mice primed at 2 weeks of age, despite signi®cant enhancement of TNP-speci®c IgG1 antibodies and in spite of their previously reported in¯uence on early-life IgG2a responses to protein antigens. 15, 16 Immunization with the T-dependent TNP-OVA formulation con®rmed the capacity of CpG-ODN to mediate induction of TNP-speci®c IgG2a antibodies in early life.
Next, we examined whether CpG-ODN could directly activate require macrophages, both in vitro 6 and in vivo. 7, 29 The contribution of T cells to anti-Ficoll B-cell responses was also demonstrated by infusing T cells into nude mice. 30 In addition, activated T cells were shown by histology to be co-localized with TNP-speci®c antibody-secreting cells. In contrast to Ficoll PS, puri®ed pneumococcal PS induced almost exclusively IgM responses. Although the weak or absent IgG responses to Pn-23 immunization observed in adult BALB/c mice do not correlate to the situation in human adults, where IgG responses can be generated by the same Pn-23 vaccine, they are in accordance with results obtained in human infants as well as in CBA/J mice. 32 Unexpectedly, CpG-ODN co-administration failed to enhance either IgM or IgG responses to unconjugated SPnPS. This failure could have been due to interference of SPnPS on CpG-ODN mediated B-cell activation, but this phenomenon was not observed even when high concentrations of SPnPS were added during in vitro incubation of splenocytes with CpG-ODN. Alternatively, CpG-ODN and SPnPS could have drained to distinct sites after s.c. injection, given the preferential localization of PS antigens in the spleen rather than in lymph nodes. 33, 34 However, the use of an i.p. immunization route, resulting in preferential draining towards the spleen, also failed to result in a CpG-mediated enhancement of antibody responses to SPnPS. Apart from being different in structure there are also differences in size between TNP-Ficoll and the various SPnPS. Thus, in order to evaluate the in¯uence of CpG-ODN supplementation under optimal conditions for both TI-2 antigens, we used antigen doses formerly reported to induce optimal B-cell responses. Comparison of similar doses (i.e. 25±50 mg) is indeed prevented by inhibition of antibody responses to high doses of SPnPS 35, 36 Interestingly, mixing the pneumococcal vaccine/CpG-ODN combination with AlOH prior to its administration did not signi®cantly alter the immunogenicity of the preparation. This was in contrast to preparations of TNP-Ficoll, TNP-OVA and several other T-dependent antigens, 15, 16 where the supplementation with AlOH was required in order effectively transmit the CpG-ODN-activating effect. These results indicate a fundamental difference in the CpG-ODN-mediated enhancement of T-dependent and TI-2 (SPnPS) immune responses. We hypothesize that the activation of innate immune responses by CpG-DNA evolved primarily as a defence against intracellular pathogens, which commonly lack TI-2 antigens, and that the failure to promote TI-2 responses more effectively may be a mechanism to avoid inducing responses to DNA or other self molecules with repeating epitopes. In contrast to the lack of in¯uence of CpG-ODN on plain SPnPS responses, it was effective on responses to certain conjugated SPnPS serotypes. To most serotypes, this CpG-ODN-mediated enhancement of IgG responses was of a modest magnitude, but evidenced by the particular enhancement of IgG2a and IgG3 responses. These results are in accordance with a recent report showing that CpG-ODN enhanced antibody responses to the HIB conjugate vaccine, but not to unconjugated HIB-PS. 13 It is interesting to note that the magnitude of the CpG-ODN-mediated enhancement of IgG2a and IgG3 titres was dependent on the pneumococcal serotype. Serotype 14-speci®c antibody responses were most susceptible to CpG-ODN activation, followed by serotype 23/23F and 56/18C (not shown). In contrast, we observed no enhancement of antibody responses to 26/6B by CpG-ODN administration. Thus, even when additional T-cell epitopes were provided, the capacity of CpG-ODN to enhance adult antibody responses to TI-2 antigens remained dependent on the nature of the SPnPS. This might suggest a distinct modulatory role of APC and/or T cells on B-cell responses to various SPn serotypes.
Unexpectedly, the CpG-mediated enhancement of SPnPS-speci®c antibody responses to the Pn11-TT glycoconjugate vaccine in adult mice was not observed when in mice immunized at 2 weeks of age. Although we cannot formally exclude that immature APC or T cells are the limiting factors for early-life antibody responses to SPnPS, as described previously for other polysaccharides (Ficoll and Dextran), 37, 38 neonatal APC and T cells have been shown to be fully receptive to CpG-ODN, both in previous experiments 15, 16 and in this report (TNP-OVA, Table 1 ). Hence, we hypothesize that a certain immaturity of early-life B cells limits the CpG-ODN modulation of early-life antibody responses to PS. 37, 39 Therefore, it appears that contradictory reports recently issued on the in¯uence of CpG-ODN on antibody responses to PS antigens may be largely explained by the various nature of the PS antigens used and the relative role for APC/T-cell interaction in the modulation of PS-speci®c B-cell responses. Whether or not CpG-ODN would be able to enhance human adult or early-life responses to plain or conjugated PS can thus not be readily predicted by preclinical studies.
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